PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-22.60%
Negative revenue growth while MRVL stands at 4.79%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-70.88%
Negative gross profit growth while MRVL is at 5.16%. Joel Greenblatt would examine cost competitiveness or demand decline.
-176.56%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-176.56%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-168.40%
Negative net income growth while MRVL stands at 2.04%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-167.50%
Negative EPS growth while MRVL is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-172.00%
Negative diluted EPS growth while MRVL is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.05%
Share reduction while MRVL is at 0.94%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-6.18%
Reduced diluted shares while MRVL is at 2.16%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-44.26%
Negative OCF growth while MRVL is at 40.47%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
148.21%
FCF growth above 1.5x MRVL's 66.17%. David Dodd would verify if the firm’s strategic investments yield superior returns.
589.93%
10Y revenue/share CAGR at 50-75% of MRVL's 847.79%. Martin Whitman would question if the firm’s offerings lag behind the competitor.
67.87%
5Y revenue/share CAGR under 50% of MRVL's 256.13%. Michael Burry would suspect a significant competitive gap or product weakness.
41.71%
3Y revenue/share CAGR under 50% of MRVL's 99.78%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
1578.93%
10Y OCF/share CAGR at 50-75% of MRVL's 2424.45%. Martin Whitman might fear a structural deficiency in operational efficiency.
272.05%
5Y OCF/share CAGR is similar to MRVL's 292.06%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
56.03%
3Y OCF/share CAGR similar to MRVL's 51.00%. Walter Schloss might see both benefiting from a rising tide or parallel expansions.
-1188.09%
Negative 10Y net income/share CAGR while MRVL is at 4039.38%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-532.96%
Negative 5Y net income/share CAGR while MRVL is 517.42%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-247.45%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
1845.86%
10Y equity/share CAGR above 1.5x MRVL's 894.41%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
131.20%
5Y equity/share CAGR above 1.5x MRVL's 48.87%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
90.55%
3Y equity/share CAGR above 1.5x MRVL's 27.55%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.24%
AR growth is negative/stable vs. MRVL's 30.75%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
2.89%
We show growth while MRVL is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
4.01%
Asset growth above 1.5x MRVL's 2.48%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-2.67%
We have a declining book value while MRVL shows 3.80%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.71%
Our R&D shrinks while MRVL invests at 4.71%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.68%
We cut SG&A while MRVL invests at 23.35%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.